Core Viewpoint - The study demonstrates that CXCR4-modified CAR-T cells enhance the efficacy of treatment for B-cell malignancies by improving tumor tracking and bone marrow homing capabilities, showing promising results in initial human trials [2][3][8]. Group 1: Research Findings - The research developed CAR-T cells with overexpressed CXCR4, which significantly improved their ability to track tumors and home to the bone marrow, thereby enhancing treatment outcomes for B-cell malignancies [3][5]. - The study found that during CAR-T cell preparation, the expression of CXCR4 on the cell surface was significantly downregulated after lentiviral-mediated gene transfer, impairing the chemotactic response to CXCL12. In contrast, enhancing CXCR4 expression (CXCR4 hi) markedly improved tumor tracking and bone marrow homing in vivo [6]. - In models of localized and systemic spread of B-cell lymphoma and multiple myeloma, CXCR4 hi CAR-T cells demonstrated superior therapeutic effects compared to second-generation CAR-T cells, even at a quarter of the infusion dose [6]. Group 2: Clinical Trials - Based on the findings, the research team initiated the first human clinical trial of autologous CXCR4 hi CD19 CAR-T cells for patients with relapsed/refractory B-cell lymphoma (NCT04684472), which showed promising results with complete and partial remissions observed in the low-dose group within the first month post-infusion [6][8]. - CXCR4 hi CD19 CAR-T cells exhibited strong tumor-clearing capabilities in patients with relapsed/refractory B-cell lymphoma without severe toxic side effects, indicating the potential of CXCR4 modification as an effective strategy to enhance CAR-T cell therapy for B-cell malignancies [8].